Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa F Licitra

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Cancer|February 8, 2020
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of lifeLaura D Locati, Donata Galbiati, Giuseppina Calareso, et al.
Pediatric Blood & Cancer|February 1, 2017
Immunohistochemical and molecular profile of salivary gland cancer in childrenLaura D Locati, Paola Collini, Martina Imbimbo, et al.
Frontiers in Immunology|July 27, 2023
Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinomaSimona Secondino, Paolo Pedrazzoli, Sabrina Basso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Cancers|June 26, 2026
Spatial Biomarker Deep Learning Model Predicts Response to PI3K Inhibition in Head and Neck CancerAntoine Desilets, Minh Tri Le, Catalina Moreno, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Cancer|February 8, 2020
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of lifeLaura D Locati, Donata Galbiati, Giuseppina Calareso, et al.
Pediatric Blood & Cancer|February 1, 2017
Immunohistochemical and molecular profile of salivary gland cancer in childrenLaura D Locati, Paola Collini, Martina Imbimbo, et al.
Frontiers in Immunology|July 27, 2023
Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinomaSimona Secondino, Paolo Pedrazzoli, Sabrina Basso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Journal of the National Cancer Institute|May 15, 2020
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040Kevin J Harrington, Denis Soulières, Christophe Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2025
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III StudyJean Bourhis, Lisa F Licitra, Barbara Burtness, et al.
Cancers|June 26, 2026
Spatial Biomarker Deep Learning Model Predicts Response to PI3K Inhibition in Head and Neck CancerAntoine Desilets, Minh Tri Le, Catalina Moreno, et al.
Cancer|April 28, 2015
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessmentMaria E Cabanillas, Martin Schlumberger, Barbara Jarzab, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Cancers|June 22, 2023
Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck CancerWyanne A Noortman, Nicolas Aide, Dennis Vriens, et al.
Pageof 3